

Brunei Darussalam

Tuberculosis profile

Population 2013

<1 million

Estimates of TB burden * 2013	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.013 (0.012–0.013)	3 (2.9–3.1)
Mortality (HIV+TB only)	0 (-)	0 (-)
Prevalence (includes HIV+TB)	0.27 (0.082–0.57)	65 (20–136)
Incidence (includes HIV+TB)	0.24 (0.21–0.28)	58 (51–66)
Incidence (HIV+TB only)		
Case detection, all forms (%)	87 (77–99)	

Estimates of MDR-TB burden * 2013	New	Retreatment
% of TB cases with MDR-TB	0.68 (0.02–3.8)	0 (0–46)
MDR-TB cases among notified pulmonary TB cases	1 (0–6)	0 (0–3)

TB case notifications 2013	New **	Relapse
Pulmonary, bacteriologically confirmed	149	6
Pulmonary, clinically diagnosed	9	0
Extrapulmonary	48	0

Total new and relapse	212
Previously treated, excluding relapses	0
Total cases notified	212

Among 212 new and relapse cases:

4 (2%) cases aged under 15 years; male:female ratio: 1.4

Reported cases of RR-/MDR-TB 2013	New	Retreatment	Total **
Cases tested for RR-/MDR-TB	159 (107%)	6 (100%)	165
Laboratory-confirmed RR-/MDR-TB cases			1
Patients started on MDR-TB treatment			0

TB/HIV 2013	Number	(%)
TB patients with known HIV status	212	(100)
HIV-positive TB patients	0	(0)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)	0	
HIV-positive TB patients on antiretroviral therapy (ART)	0	
HIV-positive people screened for TB	5	
HIV-positive people provided with IPT	0	

Treatment success rate	(%)
New and relapse cases registered in 2012	71
Previously treated cases, excluding relapse, registered in 2012	
HIV-positive TB cases, all types, registered in 2012	50
RR-/MDR-TB cases started on second-line treatment in 2011	
XDR-TB cases started on second-line treatment in 2011	


Laboratories 2013	
Smear (per 100 000 population)	0.2
Culture (per 5 million population)	12.0
Drug susceptibility testing (per 5 million population)	12.0
Sites performing Xpert MTB/RIF	0
Is second-line drug susceptibility testing available?	Yes, outside country

Financing TB control 2014	
National TB programme budget (US\$ millions)	
% Funded domestically	
% Funded internationally	
% Unfunded	

* Ranges represent uncertainty intervals


** Includes cases with unknown previous TB treatment history

(Rate per 100 000 population per year)




Mortality (excludes HIV+TB)

(Rate per 100 000 population)




Prevalence

(Rate per 100 000 population per year)




Notified (new and relapse) Incidence
Incidence (HIV+TB only)

(Number of patients)




HIV-positive TB patients
on CPT on ART

Treatment success rate (%)



New Retreatment
New and relapse Retreatment, excluding relapse
HIV-positive RR-/MDR-TB XDR-TB

Total budget (US\$ millions)



Funded domestically Funded internationally
Unfunded